Arkis BioSciences News

Arkis BioSciences® showcases successful clinical introduction of CerebroFlo™ at the 2018 American Association of Neurological Surgeons

Arkis BioSciences® exhibited at the 2018 American Association of Neurological Surgeons, announcing a successful clinical introduction of Endexo® Technology to neurosurgical use with the new and exclusive CerebroFlo™ EVD Catheter.   “Arkis’ CerebroFlo EVD catheter is a major step forward in next generation clinical technology for neurology and neuro-intensive care. We are excited to have […]


Read More

Arkis BioSciences® Brings Endexo® Technology To Neurosurgical Use With Its New CerebroFlo™ EVD Catheter

Arkis BioSciences’ new CerebroFlo™ EVD catheter garners promising clinical feedback with its introduction across the U.S. Healthcare market. Read more in the press release.


Read More

Med Device Online publishes editorial on innovative product development at Arkis

Med Device Online’s editor Bob Marshall examines the methodology of product development at Arkis BioSciences, and how Arkis is addressing unmet clinical needs.


Read More

Arkis progression to Innovation Campus covered by Knoxville Business Journal

The Knoxville Business Journal published the following announcement of the grand opening for Arkis BioSciences at the new UT Innovation Campus, adjacent to the Joint Institute for Advanced Materials.


Read More

Teknovation reports great progress at Arkis BioSciences published coverage today of the progress achieved by Arkis Biosciences.


Read More

Arkis BioSciences® opens state-of-the-art facility at Knoxville’s Innovation Campus

Arkis BioSciences was proud to announce our Grand Opening this morning at the Cherokee Farm Innovation Campus, a new high-tech facility at the University of Tennessee’s research and development campus, featuring the Joint Institute for Advanced Materials.


Read More

Arkis BioSciences® launches the new CerebroFlo™ EVD Catheter with Endexo® Technology at the 2017 Congress of Neurological Surgeons

Arkis BioSciences is launching the CerebroFlo™ EVD Catheter with Endexo® Technology at the 2017 Congress of Neurological Surgeons, booth 747. Demonstrations are available at the booth for the Single Pass Tunneling Guidewire®, the Subcutaneous Guidewire™, and the CerebroFlo EVD Catheter.


Read More

Interface Biologics Enters the Neurology Market with 510(k) Clearance of Arkis BioSciences® CerebroFlo™ EVD Catheter with Endexo® Technology

Interface Biologics Inc. (“IBI”), a privately held, commercial stage company developing innovative material science technologies that save lives and improve patient outcomes, is pleased to announce that Arkis BioSciences® has received 510(k) clearance from U.S. Food and Drug Administration (FDA) for its exclusive CerebroFlo™ EVD Catheter with IBI’s Endexo® technology.


Read More

Arkis BioSciences® achieves FDA clearance of its new CerebroFlo™ EVD Catheter with Endexo® Technology

Arkis BioSciences, a leading innovator in minimally invasive surgical instrumentation, has obtained FDA clearance of its new external ventricular drainage catheter, CerebroFlo™.  The CerebroFlo catheter has demonstrated a 99% reduction in thrombus accumulation in-vitro, and is indicated for temporary use in patients with elevated intracranial pressure, intraventricular hemorrhage, or hydrocephalic shunt infections. Arkis will debut […]


Read More

Arkis BioSciences selected as the Top Innovator at the 2017 New York Venture Summit

Arkis is honored to have been chosen as the Top Innovator at the 2017 NY Venture Summit, July 18-19th, 2017.  Be sure to visit us in the Big Apple and learn the latest news as Arkis continues to roll out its product portfolio advancing treatments for intracranial hypertension.


Read More

Contact Us

Address: 1 Momentum Way, Knoxville, TN 37920 | Tel: (844) 247-5383 (toll free)

© 2013-2018  Arkis BioSciences Inc.  All rights reserved.   |   Privacy   |   Sitemap

Arkis BioSciences is ISO 13485:2016 certified for its Medical Device Quality Management System by TUV USA, Inc. (Member of TUV NORD Group).

Go to top